USA Tom Shea, Founder and CEO of Meitheal Pharmaceuticals, discusses his career across commercial and operational roles in generic injectables and the creation of Meitheal in 2017. He highlights the company’s growth into a top-five US injectable generic player, its expansion into biosimilars, and its commitment to manufacturing investment, supply reliability,…
USA As precision medicine forces biopharma to rethink how it builds, runs, and scales laboratory and manufacturing infrastructure, the industry’s next competitive advantage will be found not in discovery, but in operational execution. Few are better positioned to make that argument than Michael Stubblefield, recently appointed CEO of PerkinElmer, who is…
USA You cannot choose between performing and transforming. The organisations that succeed can do both As AI, shifting healthcare policy, growing pressure around affordability and access, and rapidly evolving models of commercialisation reshape the pharmaceutical industry, Deborah Glasser reflects on how Sanofi is positioning its specialty care business for the next…
USA We have spent the past decade building a strong foundation, investing in the market, expanding our capabilities, and assembling an exceptional team The US generics industry remains central to the healthcare system’s efforts to improve affordability, strengthen supply resilience, and expand patient access to medicines. As Cipla enters its second…
USA If price is the only basis for adoption, biosimilars will not survive as a viable industry Tom Newcomer, SVP & Head of US Commercial, Samsung Bioepis, discusses the company’s evolution into a dedicated biosimilars developer with ten FDA approvals and a long-term commitment to improving affordability and access. He highlights…
USA Access works when all pieces are in place. Hearing directly from patients about what diagnosis or how a treatment impacts their lives is meaningful to everyone involved Scott Weintraub, Head of US Business at Alexion, AstraZeneca Rare Disease, discusses how his experience across commercial leadership, strategy, and rare disease innovation…
USA Great success stories take time, great science, resilience. We built Denali with the goal of being one of those companies, not just surviving, but ultimately thriving. Ryan Watts is the co-founder and CEO of Denali Therapeutics, a South San Francisco-based biotech he founded after leading neuroscience research at Genentech. At…
USA What motivates me is the opportunity to improve medical practice in a meaningful way, rather than simply bringing another product to market In an industry where genuine differentiation is becoming harder to find, Barry Quart sees in rademikibart the potential to address a longstanding unmet need in acute respiratory care.…
USA More than 40 years ago in 1983, the Orphan Drug Act was passed in the US to support and incentivise the development of rare disease therapies. Despite the over 6,000 orphan drug designations (ODD) granted by the FDA since then, it is estimated that only around five percent of rare…
USA A sustainable market for generics and biosimilars is the key to lowering the cost of medicine in the US, says John Murphy III, President and CEO of the Association for Accessible Medicines. Following leadership changes within the FDA, actively prioritizing generic and biosimilar medicines must remain a top focus…
USA Randy Teel, President and CEO of Arvinas, outlines the company’s evolution from a Yale-founded research platform into a leader in targeted protein degradation. He explains how Arvinas is working to develop potential new therapies using PROTAC technology that harnesses the body’s natural protein disposal system to destroy disease-causing proteins, with…
USA Harshika Sarbajna, SVP Commercial Global at Alvotech, reflects on the evolution of the US biosimilars market and the company’s strategy for scaling access across key therapeutic areas. In this interview, she discusses launch execution, payer dynamics, interchangeability, and the role of partnerships in driving adoption. She also outlines how pricing…
See our Cookie Privacy Policy Here
